Journal
BLOOD
Volume 118, Issue 13, Pages 3528-3537Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-04-346338
Keywords
-
Categories
Funding
- Leukemia and Lymphoma Research
- Experimental Cancer Medicine Center
- ATTACK EU Consortium
- MRC
- Dinwoodie Settlement Charitable Trust
- Medical Research Council [G0902209] Funding Source: researchfish
- Versus Arthritis [19225] Funding Source: researchfish
- MRC [G0902209] Funding Source: UKRI
Ask authors/readers for more resources
The function of T-cell receptor (TCR) gene modified T cells is dependent on efficient surface expression of the introduced TCR alpha/beta heterodimer. We tested whether endogenous CD3 chains are rate-limiting for TCR expression and antigen-specific T-cell function. We show that co-transfer of CD3 and TCR genes into primary murine T cells enhanced TCR expression and antigen-specific T-cell function in vitro. Peptide titration experiments showed that T cells expressing introduced CD3 and TCR genes recognized lower concentration of antigen than T cells expressing TCR only. In vivo imaging revealed that TCR+CD3 gene modified T cells infiltrated tumors faster and in larger numbers, which resulted in more rapid tumor elimination compared with T cells modified by TCR only. After tumor clearance, TCR+CD3 engineered T cells persisted in larger numbers than TCR-only T cells and mounted a more effective memory response when rechallenged with antigen. The data demonstrate that provision of additional CD3 molecules is an effective strategy to enhance the avidity, anti-tumor activity and functional memory formation of TCR gene modified T cells in vivo. (Blood. 2011;118(13):3528-3537)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available